NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE
Delisted
NBSE was delisted on the 10th of May, 2024.
38 hedge funds and large institutions have $2.52M invested in NeuBase Therapeutics, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
less capital invested
Capital invested by funds: $ → $
63% less call options, than puts
Call options by funds: $3K | Put options by funds: $8K
Holders
38
Holding in Top 10
–
Calls
$3K
Puts
$8K
Top Buyers
| 1 | +$226K | |
| 2 | +$187K | |
| 3 | +$39.9K | |
| 4 |
Goldman Sachs
New York
|
+$39K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
+$29.6K |
Top Sellers
| 1 | -$530K | |
| 2 | -$373K | |
| 3 | -$67.6K | |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$34K |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
-$34K |